NGL Fine Chem has delivered exceptional financial results for Q3, showcasing remarkable growth across key performance metrics. The fine chemicals company reported a significant surge in profitability while maintaining strong revenue momentum during the quarter. The company has also released its investor presentation for Q3 & 9M FY26 under Regulation 30, providing comprehensive insights into its operational performance.

Outstanding Financial Performance

The company's Q3 consolidated results demonstrate outstanding performance with net profit experiencing extraordinary growth. Revenue figures also reflect robust business expansion, indicating strong operational execution and market demand for the company's products.

Operational Metrics and Business Mix

The company's operational performance shows strong diversification across segments and geographies. Animal API continues to dominate the revenue mix at 92% in Q3FY26, while the company has reduced its product concentration risk with top 3 products contributing 28% compared to 37% in the previous year.

Management Commentary on Performance

According to Managing Director Rahul Nachane, the company delivered strong performance across key financial and operational metrics in Q3FY26. The management highlighted that revenue growth was driven primarily by higher volumes across the product portfolio, while price realizations remained broadly stable. The profitability profile improved significantly, supported by slight easing in raw material costs and operational efficiencies implemented across manufacturing processes.

Expansion Plans and Capital Investment

The company's ongoing capital expenditure program remains on track, with Phase II commissioning scheduled for Q1FY27. Commercial production is expected to commence from the second half of FY27, with the total investment for the project revised to approximately ₹210 crore. The company has invested ₹156 crore till Q3FY26 in its greenfield expansion at Tarapur.

Market Position and Regulatory Progress

NGL Fine Chem continues to strengthen its position in the veterinary API segment with market leadership in key products and growing presence in regulated markets. The company has made substantial progress on regulatory filings with three CEPs approved, five additional filings submitted, five ASMF approvals received, and three VMF filings completed in the United States. The company maintains strong relationships with approximately 404 customers globally and supplies to 5 of the top 10 global animal healthcare companies.

NGL Fine Chem Limited has announced the resignation of Mrs. Pallavi Pednekar from her position as Company Secretary and Compliance Officer, effective from the close of business hours on January 23, 2026. The pharmaceutical company informed both BSE Limited and National Stock Exchange of India Limited about this key managerial personnel change in compliance with regulatory requirements.

Resignation Details and Timeline

Mrs. Pallavi Pednekar submitted her resignation letter on January 5, 2026, expressing her intention to pursue career opportunities outside the organization. The resignation follows proper regulatory protocols under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Regulatory Compliance and Documentation

The company has fulfilled all mandatory disclosure requirements by providing comprehensive details to stock exchanges. Mrs. Pednekar confirmed in her resignation letter that there are no material reasons for her departure other than pursuing external career interests. The resignation letter was addressed to the Board of Directors and included proper acknowledgment of regulatory compliance requirements.

NGL Fine-Chem Limited's Managing Director Rahul Nachane (DIN: 00223346) signed the official intimation to stock exchanges, ensuring proper corporate governance protocols were followed throughout the process.

Succession Planning

The company has indicated that it is actively engaged in identifying and hiring a suitable candidate to fill the vacant position. NGL Fine-Chem Limited has committed to informing stock exchanges once the replacement process is completed, ensuring continuity in compliance and secretarial functions.

Corporate Acknowledgment

In her resignation letter, Mrs. Pednekar expressed gratitude to the Board of Directors, senior management, and colleagues for their support, guidance, and cooperation during her tenure. She specifically requested the company to arrange proper submission of required intimations to stock exchanges and filing of necessary forms with the Registrar of Companies, Mumbai, demonstrating her commitment to ensuring smooth transition procedures.